- Email: [email protected]
Continuation of Trastuzumab Beyond Progression for Her2-Positive Advanced Gastric Cancer as Second-Line Treatment
Annals of Oncology 25 (Supplement 5): v44–v74, 2014 doi:10.1093/annonc/mdu435.39
Oral Session (Oral presentations categorized by each organ) O1
17
4
Yukiya Narita1, Shigenori Kadowaki1, Hiroya Taniguchi1, Daisuke Takahari1, Takashi Ura1, Masashi Andoh1, Yasumasa Niwa2, Hiroki Hara3, Kensei Yamaguchi3, Kei Muro1 1 Department of Clinical Oncology, Aichi Cancer Center Hospital 2 Department of Endoscopy, Aichi Cancer Center Hospital 3 Department of Gastroenterology, Saitama Cancer Center Hospital
abstracts
Background: Accumulating evidence supports the benefits of continuing trastuzumab (Tmab) beyond progression (TBP) in HER2-positive (HER2+) breast cancer patients, while its significance in HER2+ advanced gastric cancer (AGC) patients remains unclear. We retrospectively investigated the association between TBP and survival outcomes in HER2+ AGC patients who had progressed after first-line Tmab-based chemotherapy.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v53/2240264 by guest on 25 October 2019
CONTINUATION OF TRASTUZUMAB BEYOND PROGRESSION FOR HER2-POSITIVE ADVANCED GASTRIC CANCER AS SECOND-LINE TREATMENT
Methods: Between January 2006 and December 2013, we identified 32 HER2+ AGC patients at two Japanese institutions who had received fluoropyrimidine-, platinum-, and Tmab-containing regimens as first-line therapy and had received irinotecan or taxanes with or without Tmab as second-line therapy. IHC3+ or IHC2 + /FISH+ tumors were defined to be HER2+. Results: Of the 32 patients, 17 patients received combination chemotherapy with Tmab (CT + T) and 15 patients were treated with chemotherapy alone (CT). Most patient characteristics were well balanced between both cohorts [age (median, 62.0 vs. 64.0 years), sex (male, 76% vs. 60%, P = 0.45), ECOG PS (0/1-2; 35%/65% vs. 47%/53%, P = 0.51), number of metastatic sites (1-2/ > 2; 59%/41% vs. 67%/33%, P = 0.73), and HER2 immunostaining (IHC3 + , 76% vs. 67%, P = 0.70)]. The response rate (RECIST ver. 1.1) was 14% and 13% in the CT + T and CT cohorts, respectively. No significant difference in PFS (median, 3.6 vs. 2.8 months; HR, 0.92; 95% CI, 0.42-2.02; P = 0.84) and OS (median, 9.5 vs. 7.6 months; HR, 0.63; 95% CI, 0.24-1.66; P = 0.35) was observed between both cohorts, while marginal improvements in PFS (median, 4.4 vs. 2.1 months; HR, 0.54; 95% CI, 0.18-1.59; P = 0.26) and OS (median, 7.8 vs. 6.7 months; HR, 0.47; 95% CI, 0.14-1.57; P = 0.22) were observed when confined to the IHC3+ subgroup. Conclusions: No significant difference was observed between the CT + T and CT cohorts for PFS and OS. Further prospective studies are warranted to clarify the benefit of TBP for HER2+ AGC.
Oral Session (Oral presentations categorized by each organ) O1
17
4
Yukiya Narita1, Shigenori Kadowaki1, Hiroya Taniguchi1, Daisuke Takahari1, Takashi Ura1, Masashi Andoh1, Yasumasa Niwa2, Hiroki Hara3, Kensei Yamaguchi3, Kei Muro1 1 Department of Clinical Oncology, Aichi Cancer Center Hospital 2 Department of Endoscopy, Aichi Cancer Center Hospital 3 Department of Gastroenterology, Saitama Cancer Center Hospital
abstracts
Background: Accumulating evidence supports the benefits of continuing trastuzumab (Tmab) beyond progression (TBP) in HER2-positive (HER2+) breast cancer patients, while its significance in HER2+ advanced gastric cancer (AGC) patients remains unclear. We retrospectively investigated the association between TBP and survival outcomes in HER2+ AGC patients who had progressed after first-line Tmab-based chemotherapy.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].
Downloaded from https://academic.oup.com/annonc/article-abstract/25/suppl_5/v53/2240264 by guest on 25 October 2019
CONTINUATION OF TRASTUZUMAB BEYOND PROGRESSION FOR HER2-POSITIVE ADVANCED GASTRIC CANCER AS SECOND-LINE TREATMENT
Methods: Between January 2006 and December 2013, we identified 32 HER2+ AGC patients at two Japanese institutions who had received fluoropyrimidine-, platinum-, and Tmab-containing regimens as first-line therapy and had received irinotecan or taxanes with or without Tmab as second-line therapy. IHC3+ or IHC2 + /FISH+ tumors were defined to be HER2+. Results: Of the 32 patients, 17 patients received combination chemotherapy with Tmab (CT + T) and 15 patients were treated with chemotherapy alone (CT). Most patient characteristics were well balanced between both cohorts [age (median, 62.0 vs. 64.0 years), sex (male, 76% vs. 60%, P = 0.45), ECOG PS (0/1-2; 35%/65% vs. 47%/53%, P = 0.51), number of metastatic sites (1-2/ > 2; 59%/41% vs. 67%/33%, P = 0.73), and HER2 immunostaining (IHC3 + , 76% vs. 67%, P = 0.70)]. The response rate (RECIST ver. 1.1) was 14% and 13% in the CT + T and CT cohorts, respectively. No significant difference in PFS (median, 3.6 vs. 2.8 months; HR, 0.92; 95% CI, 0.42-2.02; P = 0.84) and OS (median, 9.5 vs. 7.6 months; HR, 0.63; 95% CI, 0.24-1.66; P = 0.35) was observed between both cohorts, while marginal improvements in PFS (median, 4.4 vs. 2.1 months; HR, 0.54; 95% CI, 0.18-1.59; P = 0.26) and OS (median, 7.8 vs. 6.7 months; HR, 0.47; 95% CI, 0.14-1.57; P = 0.22) were observed when confined to the IHC3+ subgroup. Conclusions: No significant difference was observed between the CT + T and CT cohorts for PFS and OS. Further prospective studies are warranted to clarify the benefit of TBP for HER2+ AGC.